Phaseline

Companies › Inovio Pharmaceuticals

Inovio Pharmaceuticals: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INO-5401
DNA plasmid encoding WT1, PSMA, and hTERT tumor-associated antigens
WT1, PSMA, HGNCPhase 1GlioblastomaDec 2027
INO-9012
DNA plasmid encoding human interleukin-12 (IL-12)
IL12Phase 1GlioblastomaDec 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03491683INO-5401Phase 1GlioblastomaOncologyDec 2027
NCT03491683INO-9012Phase 1GlioblastomaOncologyDec 2027

From the company's SEC filings

Cash and short-term investments of $37m on 2026-06-30; operating cash outflow about $80m a year; runway about 6 months at that burn, to Dec 2026

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Targets

WT1 (1) PSMA (1) HGNC (1) IL12 (1)

Companies with the same targets

Clarity Pharmaceuticals C Ray Therapeutics Strand Therapeutics Sellas Life Sciences Group Nova Therapeutics Eli Lilly Fusion Pharmaceuticals Lantheus Medical Imaging Sinotau Pharmaceutical Group Norroy Bioscience

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.